Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144248 · ClinicalTrials.gov registry record · Phase 4
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT00144248 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 51 participants.
The verdict
NCT00144248, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influences clearance.
Interventions
- DRUG nevirapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2004-06-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144248
The ClinicalTrials.gov registry entry for NCT00144248 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nevirapine is the first listed.
NCT00144248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144248 about?
NCT00144248 is a clinical study titled "A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions". The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influences clearance.
What is the current status of trial NCT00144248?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2004-06-25.
What interventions are being tested in trial NCT00144248?
The interventions under investigation include: nevirapine (DRUG).
Who is sponsoring clinical trial NCT00144248?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.